JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2276
Hess Midstream
HESM
$4.96B
| $7.08M | ﹤0.01% |
364,276
-60,377
| -14% | -$1.24M |
2017 Q2
8 quarters
|
|
2277
TriNet
TNET
$2.88B
| $7.08M | ﹤0.01% |
104,746
-4,991
| -5% | -$317K |
2014 Q2
20 quarters
|
|
2278
Goodyear
GT
$1.34B
| $7.08M | ﹤0.01% |
464,312
-272,012
| -37% | -$4.59M |
2013 Q2
24 quarters
|
|
2279
CALL
Baxter International
BAX
$12.6B
| $7.06M | ﹤0.01% |
86,500
+46,500
| +116% | +$3.61M |
2018 Q3
3 quarters
|
|
2280
PUT
Kinder Morgan
KMI
$71.6B
| $7.04M | ﹤0.01% |
345,000
+164,700
| +91% | +$3.32M |
2014 Q3
19 quarters
|
|
|
RARX
2281
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $7.03M | ﹤0.01% |
244,951
+5,682
| +2% | +$130K |
2016 Q4
10 quarters
|
|
|
DERM
2282
DELISTED
Dermira, Inc.
DERM
| $7.03M | ﹤0.01% |
782,223
+338,828
| +76% | +$3.65M |
2015 Q4
14 quarters
|
|
2283
Guardant Health
GH
$22.8B
| $7.02M | ﹤0.01% |
83,405
+32,293
| +63% | +$2.47M |
2018 Q4
2 quarters
|
|
2284
PUT
Elevance Health
ELV
$86.8B
| $7M | ﹤0.01% |
24,800
-38,500
| -61% | -$10.5M |
2017 Q3
7 quarters
|
|
2285
iShares MSCI Singapore ETF
EWS
$1.43B
| $7M | ﹤0.01% |
283,962
-171,809
| -38% | -$4.15M |
2013 Q2
24 quarters
|
|
2286
Independent Bank Corp
IBCP
$795M
| $7M | ﹤0.01% |
324,512
-640
| -0.2% | -$13.9K |
2015 Q3
15 quarters
|
|
2287
CALL
Corning
GLW
$146B
| $7M | ﹤0.01% |
210,500
| – | – |
2017 Q4
6 quarters
|
|
2288
PUT
FedEx
FDX
$68.4B
| $6.97M | ﹤0.01% |
42,700
-11,900
| -22% | -$2.08M |
2016 Q4
10 quarters
|
|
|
GWB
2289
DELISTED
Great Western Bancorp, Inc.
GWB
| $6.97M | ﹤0.01% |
198,693
-195,481
| -50% | -$6.59M |
2014 Q4
18 quarters
|
|
|
ARNA
2290
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $6.96M | ﹤0.01% |
120,083
-2,759
| -2% | -$143K |
2016 Q4
10 quarters
|
|
2291
PUT
Mondelez International
MDLZ
$76.1B
| $6.95M | ﹤0.01% |
128,500
-273,500
| -68% | -$14.2M |
2014 Q2
20 quarters
|
|
2292
Pacira BioSciences
PCRX
$987M
| $6.94M | ﹤0.01% |
158,013
+144,108
| +1,036% | +$6.12M |
2013 Q2
24 quarters
|
|
2293
United Therapeutics
UTHR
$23.2B
| $6.94M | ﹤0.01% |
90,136
-128,805
| -59% | -$12M |
2013 Q2
24 quarters
|
|
2294
Ryman Hospitality Properties
RHP
$8.34B
| $6.91M | ﹤0.01% |
87,038
-156,256
| -64% | -$12.8M |
2015 Q3
15 quarters
|
|
2295
PUT
Wabtec
WAB
$49.2B
| $6.91M | ﹤0.01% |
100,000
-50,000
| -33% | -$3.54M |
2019 Q1
1 quarter
|
|
|
BID
2296
DELISTED
Sotheby's
BID
| $6.9M | ﹤0.01% |
116,767
+19,587
| +20% | +$818K |
2014 Q4
18 quarters
|
|
|
AKRX
2297
DELISTED
Akorn Inc
AKRX
| $6.89M | ﹤0.01% |
1,337,844
+360,240
| +37% | +$1.39M |
2013 Q2
24 quarters
|
|
2298
iShares US Healthcare ETF
IYH
$3.92B
| $6.88M | ﹤0.01% |
177,155
-33,075
| -16% | -$1.25M |
2013 Q2
24 quarters
|
|
|
ESPR
2299
DELISTED
Esperion Therapeutics
ESPR
| $6.88M | ﹤0.01% |
140,825
+59,425
| +73% | +$2.79M |
2015 Q3
15 quarters
|
|
2300
iShares MSCI United Kingdom ETF
EWU
$3.66B
| $6.86M | ﹤0.01% |
213,777
+141,152
| +194% | +$4.65M |
2013 Q4
22 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.